Insight Molecular Diagnostics (0KCC) Share Price & Analysis
0KCC Stock Chart & Stats
- Day’s Range
- $2.98 - $3.07
- 52-Week Range
- $2.45 - $7.77
- Previous Close
- $3.12
- Volume
- N/A
- Average Volume (3M)
- 701
- Market Cap
- $96.86M
- Enterprise Value
- $200.97M
- Total Cash (Recent Filing)
- $17.76M
- Total Debt (Recent Filing)
- $2.63M
- Price to Earnings (P/E)
- ―
- Beta
- 0.44
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.24
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Expanded Reimbursement Market
Higher permitted testing frequency expands the addressable market for transplant monitoring and strengthens the economic case for in-house kitted testing. This structural reimbursement change can support recurring test utilization, improve customer adoption, and increase the commercial opportunity over the next several quarters.
Regulatory And Clinical Progress
Progress through the FDA process, substantially greater study data, and continued agency engagement reduce key commercialization hurdles for GraftAssureDx. If authorization is achieved, the product could transition from development into a broader revenue opportunity supported by an established clinical evidence base.
Competitive Product Positioning
A claimed development lead and favorable comparative data may help differentiate the platform with transplant centers, reference laboratories, and other customers. Combined with engagement from more than half of the top ten U.S. transplant centers, this supports potential competitive positioning as commercialization advances.
Bears Say
Small And Declining Revenue Base
The company has not yet demonstrated a sustained path to operating leverage: revenue remains modest and declining, while gross and net profitability are weak. This leaves financial performance highly dependent on successful product authorization, reimbursement conversion, and a substantial increase in testing activity.
Heavy Cash Burn And Negative Equity
Large cash outflows relative to current revenue reduce financial flexibility and increase dependence on external capital. Negative equity further reflects accumulated balance-sheet erosion, so continued investment in regulatory, registry, and commercial activities may require financing before operating cash generation becomes meaningful.
Commercial Timing And Adoption Risk
The commercial opportunity remains dependent on regulatory timing and customer adoption rather than current scale. A delayed authorization would postpone larger revenue generation, while modest near-term sales indicate that reimbursement alignment, registry progress, and purchasing decisions still must convert into recurring testing volume.
Insight Molecular Diagnostics News
0KCC FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
What is Insight Molecular Diagnostics’s market cap?
When is Insight Molecular Diagnostics’s upcoming earnings report date?
How were Insight Molecular Diagnostics’s earnings last quarter?
Is Insight Molecular Diagnostics overvalued?
Does Insight Molecular Diagnostics pay dividends?
What is Insight Molecular Diagnostics’s EPS estimate?
How many shares outstanding does Insight Molecular Diagnostics have?
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
What is the TipRanks Smart Score and how is it calculated?
Insight Molecular Diagnostics Stock Smart Score
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joshua Riggs
- Employees
- 57
- Website
- imdxinc.com
- Address
- 2 International Plaza Dr., Nashville, TN, 37217, US
Insight Molecular Diagnostics (0KCC) Earnings & Revenues
0KCC Earnings Call
Earnings Call SentimentPositive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.
View all GB:0KCC earnings summaries0KCC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |
